PTAB Litigation Blog
  • Home
  • Cookie Policy
  • About
  • Advanced Topics
  • Contributors
  • Contacts
  • Design Patents
  • Discovery
  • District Court
  • Joinder
Select Page
PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation

PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation

by Cary Miller | Jul 30, 2018 | Pharmaceutical

By: J. Jason Williams and Cary Miller, Ph.D. In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not unpatentable on three separate grounds.  Shortly thereafter, Novartis filed suit...
Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira

Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira

by Cary Miller | Aug 9, 2017 | Pharmaceutical, Trial Institution

By Raffaella Faraoni, Ph.D. and Cary Miller, Ph.D. At least 19 IPRs have been filed against seven of Genentech’s patents covering its blockbuster antibody drug Herceptin® (trastuzumab). On July 27, 2017, the PTAB instituted IPRs filed by Hospira, Inc. (a subsidiary of...
PTAB Denies Joinder of IPR Petitioner That Won’t Take “Silent Understudy” Role

PTAB Denies Joinder of IPR Petitioner That Won’t Take “Silent Understudy” Role

by Cary Miller | Jul 20, 2017 | Pharmaceutical, Trial Institution

By Achim Brinker, Ph.D. and Cary Miller, Ph.D. In orders entered July 10 and 12, 2017, the PTAB instituted further inter partes review (IPR) of six Allergan Inc. (“Allergan”) patents relating to cyclosporine compositions.  Each of U.S. Patent Nos. 8,633,162,...
Known Solution to General Problem Provides Sufficient Motivation to Modify Prior Art

Known Solution to General Problem Provides Sufficient Motivation to Modify Prior Art

by Jones Day's PTAB Team | Jul 7, 2017 | Pharmaceutical

By Dominic J. Yee, Ph.D. and J. Patrick Elsevier, Ph.D. In a final written decision in Bass, et al., v. Fresenius Kabi USA, LLC (IPR2016-00254), the PTAB found that the challenged claims of Fresenius’s U.S. Patent No. 8,476,010, directed to a sterile pharmaceutical...
Federal Circuit Holds Objective Indicia Must Be Linked to Novel Features

Federal Circuit Holds Objective Indicia Must Be Linked to Novel Features

by Jones Day's PTAB Team | May 9, 2017 | Pharmaceutical

By J. Jason Williams and J. Patrick Elsevier, Ph.D. In Novartis AG v. Torrent Pharms. Ltd. (2016-1352), the Federal Circuit affirmed the PTAB’s decision in consolidated IPR proceedings (IPR2014-00784, IPR2015-00518) invalidating all claims of U.S. Patent 8,324,283. In...
Product-by-Process Claims Invalid when the Process Does Not Impart Structural or Functional Differences

Product-by-Process Claims Invalid when the Process Does Not Impart Structural or Functional Differences

by Cary Miller | May 5, 2017 | Pharmaceutical

By Kunyong Yang and Cary Miller, Ph.D. The PTAB issued a final written decision in IPR2016-00006, holding claims 1–22 of U.S. Patent No. 8,497,393 (“the ’393 patent”) unpatentable under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a).  All of the claims are...
« Older Entries
Next Entries »

About this blog

Follow us on Twitter

Categories

  • 325(d) issues
  • Amendment Practice
  • CBMs
  • Claim Construction
  • Design Patents
  • Discovery
  • District Court
  • Estoppel
  • Evidentiary Issues
  • Expert Witnesses
  • Federal Circuit
  • Federal Circuit Appeal
  • Final Written Decisions
  • Joinder
  • Motions Practice
  • Other News
  • Patent Eligible Subject Matter
  • Petitions
  • PGR
  • Pharmaceutical
  • Preliminary Responses
  • Prior Art Issues
  • PTAB News
  • PTAB Trial Basics
  • Real Party in Interest
  • Request for Reconsideration
  • Standing
  • Stay
  • Time Limits
  • Trial Institution
  • Uncategorized

Archives

Links

www.jonesday.com

About Jones Day's Intellectual Property Practice

Subscribe to Jones Day publications

  • Privacy
  • Facebook
  • Twitter
  • RSS

The opinions expressed are those of the authors and do not necessarily reflect the views of Jones Day or its clients. The posts and information provided are for general information purposes and are not intended to be and should not be taken as legal advice.